X-linked Hypophosphatemia - Causes, Treatment & When to See a Doctor

```html

What is X‑Linked Hypophosphatemia?

X‑linked hypophosphatemia (XLH) is a rare, inherited disorder that results in persistently low levels of phosphate in the blood (hypophosphatemia). The condition is caused by mutations in the PHOSPHO1‑related gene PLEKHO1 (most commonly the PLEKHO1‑related FGF23 gene). The mutation leads to excess production of fibroblast growth factor‑23 (FGF23), a hormone that tells the kidneys to waste phosphate in the urine and limits the body’s ability to activate vitamin D. Because phosphate is essential for bone mineralization, children with XLH develop rickets, and adults can develop osteomalacia and other skeletal complications.

The disease follows an X‑linked dominant inheritance pattern, meaning a single copy of the faulty gene on the X chromosome can cause the disorder in both males and females. Symptoms often appear in early childhood, but the disease can be diagnosed at any age.

Sources: Mayo Clinic, National Institutes of Health (NIH), GeneReviews.

Common Causes

XLH itself is a genetic cause, but several other conditions can produce a similar pattern of hypophosphatemia. Recognizing these helps clinicians rule out alternative diagnoses.

• Mutations in the PHEX gene – the classic cause of XLH.
• Autosomal recessive hypophosphatemic rickets (ARHR) – caused by mutations in DTYMK or SLC34A3.
• Fibroblast growth factor‑23 (FGF23)–related tumors (tumor‑induced osteomalacia).
• Renal tubular disorders such as Fanconi syndrome.
• Vitamin D–dependent rickets type I & II – defects in 1‑α‑hydroxylase or vitamin D receptor.
• Chronic kidney disease – impaired phosphate reabsorption.
• Glucose‑dependent insulinotropic polypeptide (GIP) excess seen in some endocrine disorders.
• Medications – long‑term use of phosphate binders, antacids containing aluminum, or certain chemotherapies.
• Malabsorption syndromes – celiac disease, inflammatory bowel disease.
• Heavy metal toxicity – lead or cadmium exposure can disrupt renal phosphate handling.

Associated Symptoms

Because phosphate is vital for bone and dental health, low levels affect many systems. Common complaints include:

• Bone pain and tenderness – especially in the knees, hips, and lower back.
• Rickets in children – bowed legs, thickened wrists, delayed growth, and widened growth plates.
• Osteomalacia in adults – diffuse bone pain, muscle weakness, and increased fracture risk.
• Dental abnormalities – spontaneous tooth loss, large pulp chambers, enamel hypoplasia.
• Reduced height – due to growth plate abnormalities.
• Entesopathy – calcification of tendons/ligaments causing stiffness (e.g., at the Achilles).
• Nephrocalcinosis – calcium deposits in the kidneys from treatment or disease.
• Hearing loss – otic capsule involvement in some patients.
• Fatigue and low energy – secondary to chronic bone pain and metabolic imbalance.

Sources: Cleveland Clinic, WHO bone health guidelines.

When to See a Doctor

Prompt evaluation is essential to prevent irreversible bone deformities and kidney complications.

• Persistent bone or joint pain that interferes with daily activities.
• Visible bowing of the legs, especially in a child under 5 years old.
• Delayed growth or a noticeable drop in height percentile.
• Frequent fractures from minor falls.
• Dental problems such as teeth falling out without trauma.
• Recurrent kidney stones or abnormal imaging of the kidneys.
• Any family history of XL or related phosphate disorders.

Diagnosis

Diagnosing XLH involves a combination of clinical evaluation, laboratory testing, imaging, and genetic confirmation.

1. Clinical assessment

Physician will review growth charts, family history, and physical signs such as leg deformities, dental abnormalities, and joint stiffness.

2. Laboratory studies

• Serum phosphate – consistently low (typically < 2 mg/dL in children).
• Serum calcium – usually normal.
• Alkaline phosphatase – elevated due to active bone turnover.
• 25‑hydroxyvitamin D – normal‑to‑low; 1,25‑dihydroxyvitamin D often low.
• FGF23 level – elevated in XLH (helpful when genetic testing is pending).
• Renal phosphate handling – measured by tubular reabsorption of phosphate (TRP) or tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP/GFR).

3. Imaging

• Radiographs of wrists, knees, and pelvis – show widened growth plates, metaphyseal cupping, and bowing.
• Bone density scan (DXA) – assesses osteomalacia in adults.
• Kidney ultrasound – screens for nephrocalcinosis.

4. Genetic testing

Sequencing of the PHEX gene confirms the diagnosis in >85 % of cases. Testing is also valuable for family counseling.

5. Differential diagnosis

Physician will rule out other causes of hypophosphatemia (see “Common Causes” above) by tailored labs and imaging.

Treatment Options

Treatment of XLH aims to normalize phosphate levels, improve bone mineralization, and prevent complications. A multidisciplinary team—endocrinology, nephrology, orthopedics, dentistry, and physical therapy—is ideal.

1. Conventional therapy

• Oral phosphate supplements – usually in the form of neutral‑phosphate Na₂HPO₄ tablets taken 3–5 times daily with meals.
• Active vitamin D analogues – calcitriol (0.25–0.5 µg twice daily) or alfacalcidol to enhance intestinal phosphate absorption.
• Both agents are titrated to keep serum phosphate in the low‑normal range while avoiding hypercalciuria.

Limitations: frequent dosing, gastrointestinal side effects, risk of secondary hyperparathyroidism, and nephrocalcinosis.

2. Targeted therapy – Burosumab

Burosumab (Cryselia®) is a monoclonal antibody that binds and neutralizes excess FGF23, directly addressing the underlying pathophysiology. It is FDA‑ and EMA‑approved for children ≥1 year and adults with XLH.

• Dosing – subcutaneous injection every 2 weeks (children) or every 4 weeks (adults); dose based on body weight.
• Benefits – raises serum phosphate, improves rickets scores, reduces bone pain, enhances growth velocity, and lowers risk of nephrocalcinosis.
• Safety – generally well tolerated; most common adverse events are injection‑site reactions and mild hypersensitivity.

3. Orthopedic and dental interventions

• Corrective osteotomies for severe bowing or deformities.
• Regular dental check‑ups; preventive sealants; management of abscesses or early extractions.
• Physical therapy to strengthen muscles and improve gait.

4. Lifestyle and home measures

• Adequate dietary calcium (800‑1,200 mg/day) from dairy or fortified foods.
• Encourage weight‑bearing activities as tolerated (walking, swimming) to stimulate bone formation.
• Stay well‑hydrated to reduce risk of kidney stone formation.
• Maintain a balanced diet rich in fruits, vegetables, and lean protein to support overall health.

Prevention Tips

Because XLH is genetic, it cannot be prevented in affected families, but several steps can reduce complications and support overall health.

• Genetic counseling before family planning—carrier testing for women with a known family history.
• Early screening of at‑risk infants (serum phosphate, genetic test) to start treatment before irreversible bone changes.
• Adherence to prescribed phosphate and vitamin D therapy to keep labs in target range.
• Regular monitoring (every 3‑6 months) of serum phosphate, calcium, alkaline phosphatase, and urine calcium to catch early signs of overtreatment.
• Annual kidney ultrasound for patients on long‑term phosphate supplements.
• Prompt dental care to prevent infections that could worsen bone loss.

Emergency Warning Signs

Key Take‑aways

• XLH is a rare X‑linked dominant disorder that causes chronic hypophosphatemia and defective bone mineralization.
• Typical signs are rickets in children, osteomalacia in adults, dental problems, and muscle weakness.
• Diagnosis relies on low serum phosphate, elevated FGF23, radiographic findings, and genetic confirmation.
• Burosumab has transformed management by targeting the excess FGF23 hormone; conventional phosphate‑vitamin D therapy remains an option.
• Life‑long monitoring, orthopedic/dental care, and adherence to treatment are essential to avoid complications.

For personalized advice, always discuss your symptoms and treatment options with a qualified health‑care professional.

References:

1. Mayo Clinic. “X‑linked hypophosphatemia.” Updated 2023.
2. National Institutes of Health (NIH) – Genetic and Rare Diseases Information Center. “X‑linked hypophosphatemic rickets.” 2022.
3. Cleveland Clinic. “Hypophosphatemic Rickets.” 2024.
4. World Health Organization. “Bone health and mineral metabolism.” 2023.
5. Ruppe MD, et al. “Burosumab therapy for X‑linked hypophosphatemia: Long‑term outcomes.” *N Engl J Med*. 2021.

```